Date: 2017-11-29
Type of information: Private placement
Company: Y-mAbs Therapeutics (USA - NY)
Investors: HBM Healthcare Investments (Switzerland) existing investors Sofinnova Ventures (USA) Scopia Capital Management (USA)
Amount: $80 million
Funding type: private placement
Planned used:
- The proceeds of the financing will be used to advance the development of YmAbs portfolio of late-stage oncology compounds (burtomab and naxitamab), establish sales and marketing capabilities, and bolster general working capital. The financing will strengthen the Company’s balance sheet and position it for continued progress as it initiates and completes additional clinical trials targeting a variety of cancers.
Others:
- • On November 29, 2017, Y-mAbs Therapeutics announced that the company has completed an extended closing of an additional $30 million in a private equity placement, adding institutional investors Sofinnova Ventures and Scopia Capital Management to its list of shareholders. Together, with the $50 million raised in the first closing, the company has now raised $80 million pursuant to this private placement round.
- • On October 24, 2017, Y-mAbs Therapeutics announced that it has closed a private placement among HBM Healthcare Investments and its current shareholders raising $50 million.
Therapeutic area: Cancer - Oncology
Is general: Yes
